Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): A review: Review article

Headache

Volumn 50, Issue 2, 2010, Pages 264-272

  Gillman, P Ken ^a  

^a NONE   (Australia)

Author keywords

Serotonin syndrome; Serotonin toxicity; SSRIs; Triptans

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ANTIMIGRAINE AGENT; ASCORBIC ACID; BROMOCRIPTINE; BUSPIRONE; CABERGOLINE; CITALOPRAM; CYPROHEPTADINE; DIHYDROERGOTAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; ERGOTAMINE DERIVATIVE; LISURIDE; LYSERGIDE; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NARATRIPTAN; NEFAZODONE; PERGOLIDE; SEROTONIN 1 ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SUMATRIPTAN; TRIPTAN DERIVATIVE; UNINDEXED DRUG; ZOLMITRIPTAN;

BODY TEMPERATURE; DEATH; DRUG OVERDOSE; DRUG SAFETY; DYSKINESIA; DYSTONIA; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HYPERTHERMIA; MEDICAL LITERATURE; MIGRAINE; MORBIDITY; NEUROPHARMACOLOGY; NONHUMAN; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; REVIEW; SEROTONIN SYNDROME; SEROTONINERGIC SYSTEM;

CENTRAL NERVOUS SYSTEM; DRUG INTERACTIONS; HUMANS; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN AGONISTS; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS; SYNAPTIC TRANSMISSION; TRYPTAMINES;

EID: 75849162515     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2009.01575.x     Document Type: Review

References (77)

1. Wenzel RG, Tepper S, Korab WE, Freitag F. Serotonin syndrome risks when combining SSRI/SNRI drugs and triptans: Is the FDA's alert warranted. Ann Pharmacother. 2008 42: 1692 1696.
2. Gillman PK. Serotonin toxicity. Headache. 2008 48: 640 641.
3. Shapiro RE, Tepper SJ. The serotonin syndrome, triptans, and the potential for drug-drug interactions. Headache. 2007 47: 266 269.
4. Sclar DA, Robison LM, Skaer TL. Concomitant triptan and SSRI or SNRI use: A risk for serotonin syndrome. Headache. 2007 48: 126 129.
5. Anon. US Food and Drug Administration. Information for healthcare professionals. Selective serotonin reuptake inhibitors (SSRIs), selective serotonin-norepinephrine reuptake inhibitors (SNRIs), 5-hydroxytryptamine receptor agonists (triptans). 2006. Available at: http://www.fda.gov/cder/drug/ InfoSheets/HCP/triptansHCP.htm.
6. Anon. US Food and Drug Administration. FDA public health advisory. Combined use of 5-hydroxytryptamine receptor agonists (triptans), selective serotonin reuptake inhibitors (SSRIs) or selective serotonin/norepinephrine reuptake inhibitors (SNRIs) may result in life-threatening serotonin syndrome. 2007. Available at: http://www.fda.gov/cder/drug/advisory/SSRI-SS200607.htm.
7. Evans RW. The FDA alert on serotonin syndrome with combined use of SSRIs or SNRIs and Triptans: An analysis of the 29 case reports. MedGenMed. 2007 9: 48.
8. Evans RW. Concomitant triptan and SSRI or SNRI use: What is the risk for serotonin syndrome? Headache. 2008 48: 639 640.
9. Gillman PK. A review of serotonin toxicity data: Implications for the mechanisms of antidepressant drug action. Biol Psychiat. 2006 59: 1046 1051.
10. Gillman PK. A systematic review of the serotonergic effects of mirtazapine in humans: Implications for its dual action status. Hum Psychopharmacol. 2006 21: 117 125.
11. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth. 2005 95: 434 441.
12. Isbister GK, Hackett LP, Dawson AH, Whyte IM, Smith AJ. Moclobemide poisoning: Toxicokinetics and occurrence of serotonin toxicity. Br J Clin Pharmacol. 2003 56: 441 450.
13. Whyte IM, Dawson AH. Redefining the serotonin syndrome. J Toxicol Clin Toxicol. 2002 40: 668 669.
14. Gillman PK. Serotonin syndrome: History and risk. Fundam Clin Pharmacol. 1998 12: 482 491.
15. Isbister GK, Buckley NA. The pathophysiology of serotonin toxicity in animals and humans: Implications for diagnosis and treatment. Clin Neuropharmacol. 2005 28: 205 214.
16. Whyte IM. Serotonin toxicity (syndrome). In: Dart RC, ed. Medical Toxicology. Baltimore, MD: Lippincott Williams & Wilkins 2004: 103 106.
17. Dunkley EJC, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. Hunter Serotonin Toxicity Criteria: A simple and accurate diagnostic decision rule for serotonin toxicity. Q J Med. 2003 96: 635 642.
18. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005 352: 1112 1120.
19. Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: A review. Expert Opin Drug Saf. 2008 7: 587 596.
20. Isbister GK, Buckley NA, Whyte IM. Serotonin toxicity: A practical approach to diagnosis and treatment. Med J Aust. 2007 187: 361 365.
21. Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol (Oxf). 1999 13: 100 109.
22. Stanford SC, Stanford BJ, Gillman PK. Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: An update on a case report of post-operative delirium. J Psychopharmacol (Oxf). 2009 [Epub ahead of print]. doi:10.1177/0269881109105450.
23. Gillman PK. Extracting value from case reports: Lessons from Serotonin toxicity (serotonin syndrome). Anaesthesia. 2006 61: 419 422.
24. McDaniel WW. Serotonin syndrome: Early management with cyproheptadine. Ann Pharmacother. 2001 35: 870 873.
25. Isbister GK, Dawson AH, Whyte IM. Comment: Serotonin syndrome induced by fluvoxamine and mirtazapine. Ann Pharmacother. 2001 35: 1674 1675.
26. Gillman PK. Methylene Blue implicated in potentially fatal serotonin toxicity. Anaesthesia. 2006 61: 1013 1014.
27. Yu AM. Indolealkylamines: Biotransformations and potential drug-drug interactions. Aaps J. 2008 10: 242 253.
28. Mantegani S, Brambilla E, Varasi M. Ergoline derivatives: Receptor affinity and selectivity. Farmaco. 1999 54: 288 296.
29. Ma Z, Zhang G, Jenney C, Krishnamoorthy S, Tao R. Characterization of serotonin-toxicity syndrome (toxidrome) elicited by 5-hydroxy-l-tryptophan in clorgyline-pretreated rats. Eur J Pharmacol. 2008 588: 198 206.
30. Nisijima K, Yoshino T, Yui K, Katoh S. Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Res. 2001 890: 23 31.
31. Mathew NT, Tietjen GE, Lucker C. Serotonin syndrome complicating migraine pharmacotherapy. Cephalalgia. 1996 16: 323 327.
32. Eadie MJ. Convulsive ergotism: Epidemics of the serotonin syndrome? Lancet Neurol. 2003 2: 429 434.
33. Barger G. Ergot and Ergotism. London: Gurney & Jackson 1931.
34. Tissot SA. Traité des nerves et de leurs maladies. Reprint of 1st edition (1780). Paris: Didot 1840.
35. Rowell PP, Larson BT. Ergocryptine and other ergot alkaloids stimulate the release of [3H]dopamine from rat striatal synaptosomes. J Anim Sci. 1999 77: 1800 1806.
36. Fantegrossi WE, Murnane KS, Reissig CJ. The behavioral pharmacology of hallucinogens. Biochem Pharmacol. 2008 75: 17 33.
37. Sadzot B, Baraban JM, Glennon RA. Hallucinogenic drug interactions at human brain 5-HT2 receptors: Implications for treating LSD-induced hallucinogenesis. Psychopharmacol (Berl). 1989 98: 495 499.
38. Klock JC, Boerner U, Becker CE. Coma, hyperthermia and bleeding associated with massive LSD overdose. A report of eight cases. West J Med. 1974 120: 183 188.
39. Friedman SA, Hirsch SE. Extreme hyperthermia after LSD ingestion. JAMA. 1971 217: 1549 1550.
40. Schmid CL, Raehal KM, Bohn LM. Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Proc Natl Acad Sci USA. 2008 105: 1079 1084.
41. Abbas A, Roth BL. Arresting serotonin. Proc Natl Acad Sci USA. 2008 105: 831 832.
42. Snider SR, Hutt CS, Stein B, Fahn S. Increase in brain serotonin produced by bromocryptine. Neurosci Lett. 1975 1: 237 241.
43. Blier P, Seletti B, Gilbert F, Young SN, Benkelfat C. Serotonin 1A receptor activation and hypothermia in humans: Lack of evidence for a presynaptic mediation. Neuropsychopharmacology. 2002 27: 301 308.
44. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999 38: 1083 1152.
45. Goldberg RJ, Huk M. Serotonin syndrome from trazadone and buspirone. Psychosomatics. 1992 33: 235 236.
46. Baetz M, Malcolm D. Serotonin syndrome from fluvoxamine and buspirone. Can J Psychiatry. 1995 40: 428 429.
47. Spigset O, Adielsson G. Combined serotonin syndrome and hyponatraemia caused by a citalopram buspirone interaction. Int Clin Psychopharmacol. 1997 12: 61 63.
48. Manos GH. Possible serotonin syndrome associated with buspirone added to fluoxetine. Ann Pharmacother. 2000 34: 871 874.
49. Jagestedt M, von Bahr C. [Combination of serotonergic agents resulted in severe adverse effects]. Lakartidningen. 2004 101: 1618 1619.
50. Bonin B, Vandel P, Vandel S, Sechter D, Bizouard P. Serotonin syndrome after sertraline, buspirone and loxapine? Therapie. 1999 54: 269 271.
51. Nijhawan PK, Katz G, Winter S. Psychiatric illness and the serotonin syndrome: An emerging adverse drug effect leading to intensive care unit admission. Crit Care Med. 1996 24: 1086 1089.
52. Lantz MS. Serotonin syndrome. A common but often unrecognized psychiatric condition. Geriatrics. 2001 56: 52 53.
53. Lambert GA. Preclinical neuropharmacology of naratriptan. CNS Drug Rev. 2005 11: 289 316.
54. Bonhaus DW, Weinhardt KK, Taylor M. RS-102221: A novel high affinity and selective, 5-HT2C receptor antagonist. Neuropharmacology. 1997 36: 621 629.
55. Boess FG, Martin IL. Molecular biology of 5-HT receptors. Neuropharmacology. 1994 33: 275 317.
56. Domenech T, Beleta J, Palacios JM. Characterization of human serotonin 1D and 1B receptors using [3H]-GR-125743, a novel radiolabelled serotonin 5HT1D/1B receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol. 1997 356: 328 334.
57. Humphrey PP, Feniuk W, Marriott AS, Tanner RJ, Jackson MR, Tucker ML. Preclinical studies on the anti-migraine drug, sumatriptan. Eur Neurol. 1991 31: 282 290.
58. Connor HE, Feniuk W, Beattie DT. Naratriptan: Biological profile in animal models relevant to migraine. Cephalalgia. 1997 17: 145 152.
59. Martin GR. Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine. Cephalalgia. 1997 17 (Suppl. 18 4 14.
60. Hojer J, Personne M, Skagius AS, Hansson O. [Serotonin syndrome-Several cases of this often overlooked diagnosis]. Tidsskr Nor Laegeforen. 2002 122: 1660 1663.
61. Hendrix Y, van Zagten MS. [Serotonin syndrome as a result of concomitant use of paroxetine and sumatriptan]. Ned Tijdschr Geneeskd. 2005 149: 888 890. (Pubitemid 40545540)
62. le Comte M, Wensveen B. [Serotonin syndrome as a result of concomitant use of paroxetine and sumatriptan]. Ned Tijdschr Geneeskd. 2005 149: 1654.
63. Bonetto N, Santelli L, Battistin L, Cagnin A. Serotonin syndrome and rhabdomyolysis induced by concomitant use of triptans, fluoxetine and hypericum. Cephalalgia. 2007 27: 1421 1423.
64. Soldin OP, Tonning JM. Serotonin syndrome associated with triptan monotherapy. N Engl J Med. 2008 358: 2185 2186.
65. Lucas C, Donnet A. Serotininergic syndrome due to zolmitriptan: First two cases. Cephalalgia. 2001 21: 421.
66. Blier P, Bergeron R. The safety of concomitant use of sumatriptan and antidepressant treatments. J Clin Psychopharmacol. 1995 15: 106 109.
67. Putnam GP, O'Quinn S, Bolden-Watson CP, Davis RL, Gutterman DL, Fox AW. Migraine polypharmacy and the tolerability of sumatriptan: A large-scale, prospective study. Cephalalgia. 1999 19: 668 675.
68. Gardner DM, Lynd LD. Sumatriptan contraindications and the serotonin syndrome. Ann Pharmacother. 1998 32: 33 38.
69. Hettiarachchi J, Turrall K. Concomitant eletriptan and selective serotonin reuptake inhibitor therapy for migraine patients: A review of seven clinical studies. Cephalalgia. 2001 21: 431.
70. Gillman PK. Moclobemide and the risk of serotonin toxicity (or serotonin syndrome). CNS Drug Rev. 2004 10: 83 85.
71. Gillman PK. Mirtazapine: Not a dual action antidepressant? Aust N Z J Psychiatry. 2004 38: 266 267.
72. Gillman PK. Reply to associate professor Norman. Aust N Z J Psychiatry. 2004 38: 269.
73. Fox MA, Jensen CL, Murphy DL. Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice. Int J Neuropsychopharmacol. 2009 1 11.
74. Cussac D, Boutet-Robinet E, Ailhaud MC. Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Eur J Pharmacol. 2008 594: 32 38.
75. Gonzalez-Maeso J, Weisstaub NV, Zhou M. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron. 2007 53: 439 452.
76. Denys D, Van Nieuwerburgh F, Deforce D, Westenberg HG. Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. J Clin Psychiatry. 2007 68: 747 753.
77. MHRA. Methylthioninium chloride (methylene blue): CNS toxicity with serotonergic drugs. Drug Safety Update. 2008 1: 5.